Early research (Phase 1)Study completedNCT02338622What this trial is testingTrial of Olaparib in Combination With AZD5363 (ComPAKT)Who this might be right forAdvanced Cancer Royal Marsden NHS Foundation Trust 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT01638546What this trial is testingTemozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerWho this might be right forRecurrent Lung Small Cell Carcinoma National Cancer Institute (NCI) 97
Testing effectiveness (Phase 2)Study completedNCT04826341What this trial is testingA Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsWho this might be right forHRD CancerSCLCAdvanced Solid Tumors National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03880019What this trial is testingA Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaWho this might be right forStage III Uterine Corpus Leiomyosarcoma AJCC v8Stage IV Uterine Corpus Leiomyosarcoma AJCC v8Uterine Corpus Leiomyosarcoma National Cancer Institute (NCI) 23
Testing effectiveness (Phase 2)Looking for participantsNCT04716686What this trial is testingNiraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaWho this might be right forEndometrial CarcinomaSerous Carcinoma Shandong University 83
Testing effectiveness (Phase 2)Ended earlyNCT02412371What this trial is testingA Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer Stage III AbbVie 48
Testing effectiveness (Phase 2)Study completedNCT05751629What this trial is testingStudy to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerWho this might be right forOvarian Neoplasm Tesaro, Inc. 41
Early research (Phase 1)Study completedNCT03057145What this trial is testingCombination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor Geoffrey Shapiro, MD, PhD 29
Testing effectiveness (Phase 2)Study completedNCT01583543What this trial is testingOlaparib in Adults With Recurrent/Metastatic Ewing's SarcomaWho this might be right forEwing's Sarcoma Massachusetts General Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT05704621What this trial is testingSecondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor MaintenanceWho this might be right forOvarian CancerDrug Related Neoplasm/Cancer Korea University Guro Hospital 124
Testing effectiveness (Phase 2)Study completedNCT04174716What this trial is testingBasket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)Who this might be right forSolid TumorsHomologous Recombination Repair Gene MutationHomologous Recombination Deficiency Idience Co., Ltd. 108
Large-scale testing (Phase 3)Study completedNCT02855944What this trial is testingARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsWho this might be right forOvarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more pharmaand GmbH 349
Testing effectiveness (Phase 2)WithdrawnNCT06365970What this trial is testingNiraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal CancersWho this might be right forMMR-D/MSI-H Colorectal Cancers Ibrahim Halil Sahin
Not applicableLooking for participantsNCT06588322What this trial is testingDetection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance TherapyWho this might be right forOvarian Cancer Institut Claudius Regaud 130
Early research (Phase 1)Study completedNCT00994071What this trial is testingA Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS TumorsWho this might be right forMedulloblastomaPontine GliomaEpendymoma+2 more National Cancer Institute (NCI) 9
Early research (Phase 1)Study completedNCT01589419What this trial is testingA Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal CancerWho this might be right forLocally Advanced Rectal Cancer AbbVie (prior sponsor, Abbott) 32
Testing effectiveness (Phase 2)Looking for participantsNCT06582628What this trial is testingTalazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)Who this might be right forMetastatic Prostate Cancer Fundacion Oncosur 78
Large-scale testing (Phase 3)Study completedNCT02000622What this trial is testingAssessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.Who this might be right forBreast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation AstraZeneca 302
Not applicableUnknownNCT05310370What this trial is testingHRD and Resistance to PAPPi in EOC PatientsWho this might be right forEpithelial Ovarian CancerHomologous Recombination DeficiencyHomologous Recombination Repair Gene Mutation+4 more Lei Li 400
Testing effectiveness (Phase 2)Ended earlyNCT04972110What this trial is testingStudy of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor, Adult Repare Therapeutics 156